

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ITW



In re Application of: Yann Echelard et al..

Serial No.: 10/619,055

Group No.: 1632

Filed: July 14, 2003

Examiner: Unknown

For: **METHOD FOR THE RAPID SELECTION OF HOMOZYGOS PRIMARY CELL LINES FOR THE PRODUCTION OF TRANSGENIC ANIMALS BY SOMATIC CELL NUCLEAR TRANSFER**

Attorney Docket Number: **GTC-208**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING APPLICATION OR BEFORE MAILING OF A
FIRST OFFICE ACTION ON THE MERITS (37 CFR 1.97(b))**

1. Authority

Pursuant to 37 CFR § § 1.56 and 1.97-1.99, the Applicant cites to the Examiner documents containing information which, in good-faith judgment of the Applicant, may be relevant to the subject matter claimed in the above-identified application. The Applicant also encloses copies of the English-language cited documents.

In submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, or the extent of any search performed, or that more relevant information does not exist.

In submitting this Information Disclosure Statement, the Applicant makes no representation that any document cited in this Information Disclosure Statement is, or is considered to be prior art as defined by 35 USC § § 102 and 103.

2. Time of Transmittal of Accompanying Information Disclosure Statement

The Information Disclosure Statement transmitted herewith is being filed *after* three

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that on March 2, 2005 this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dawn C. Greenaway

months of the filing date of this national application but *before* the mailing date of the first Office action on the merits.

It is Applicant's understanding that no fee is due; however, if the Applicant is incorrect, please charge any necessary fees for the above-captioned application to Deposit Account No. 502092.

The Applicant respectfully requests that:

- a. The Examiner consider the cited information in reaching a determination concerning the patentability of the pending claims; and
- b. The enclosed Form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

The person making this statement is the attorney who signs below on the basis of the information in the attorney's file.

Dated: 3/2/05

Respectfully submitted,

By: 

Byron V. Olsen, Reg. No. 42,960
Attorney for Applicants
175 Crossing Blvd., Suite 410
Framingham, MA 01702
Tel. #(508) 370-5150 Fax #(508) 370-3797

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

*Complete if Known***INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(use as many sheets as necessary)*

Sheet 1 of 6

Application Number	10/619,055
Filing Date	July 14, 2003
First Named Inventor	Yann Echelard
Art Unit	1632
Examiner Name	
Attorney Docket Number	GTC-208

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Document Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)						

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov, or MPEP 901/04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/619,055
				Filing Date	July 14, 2003
				First Named Inventor	Yann Echelard
				Group Art Unit	1632
Examiner Name					
Sheet	2	of	6	Attorney Docket Number	GTC-208

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Alberio R, <i>et al.</i> , <i>Mammalian Oocyte Activation: Lessons from the Sperm and Implications for Nuclear Transfer</i> , INT J DEV BIOL 2001; 45: 797-809.	
		Arroyo, A. <i>et al.</i> , <i>In Vivo Roles Of Integrins During Leukocyte Development And Traffic: Insights From The Analysis Of Mice Chimeric For α_5, α_v, and α_4 Integrins</i> . THE JI 2000;165: 4667-4675.	
		Baguisi A, <i>et al.</i> , <i>Production of Goats by Somatic Cell Nuclear Transfer</i> , NAT BIOTECH 1999; 17: 4 56-461.	
		Bondioli K, <i>et al.</i> , <i>Production of Identical Bovine Offspring by Nuclear Transfer</i> , THERIOGENOLOGY 1990; 33: 165-174.	
		Byrd, N, <i>et al.</i> , <i>Hedgehog Is Required For Murine Yolk Sac Angiogenesis</i> . DEVELOPMENT 2002; 129: 361-372.	
		Cibelli JB, <i>et al.</i> , <i>Cloned Transgenic Calves Produced From Nonquiescent Fetal Fibroblasts</i> . SCIENCE 1998; 280: 1256-1258.	
		Gavin, W.G., <i>Gene Transfer Into Goat Embryos</i> , TRANSGENIC ANIMALS – GENERATION AND USE, L. M. Houdebine ed., (Harwood Academic Publishers GmbH., 1996).	
		Helgason, C <i>et al.</i> , <i>Targeted Disruption Of SHIP Leads To Hemopoietic Perturbations, Lung Pathology, And A Shortened Life Span</i> . GENES & DEV. 1998; 12: 1610-1620.	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901/04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	3	of	6
-------	---	----	---

Application Number	10/619,055
--------------------	------------

Filing Date	July 14, 2003
-------------	---------------

First Named Inventor	Yann Echelard
----------------------	---------------

Art Unit	1632
----------	------

Examiner Name	
---------------	--

Attorney Docket Number	GTC-208
------------------------	---------

		Hu, J.-F, et al., <i>Genomic Deletion Of An Imprint Maintenance Element Abolishes Imprinting Of Both Insulin-Like Growth Factor II And H19</i> . J. BIOL. CHEM. 1997; 272: 20715-20720.	
		Hwang, H.-Y, et al., <i>Creation Of Homozygous Mutants Of Leishmania Donovanii With Single Targeting Constructs</i> . J. BIOL. CHEM. 1996; 271: 30840-30846.	
		Jain, M, et al., <i>Targeted Inactivation Of GαI Does Not Alter Cardiac Function Or β-Adrenergic Sensitivity</i> . AM. J. PHYSIOL. 2001; 280: 569H-575.	
		Kasinathan P, et al., <i>Effect of Fibroblast Donor Cell Age and Cell Cycle on Development of Bovine Nuclear Transfer Embryos In Vitro</i> , BIOL REPROD. 2001; 64(5): 1487-1493.	
		Kasinathan P, et al., <i>Production of Calves from G1 Fibroblasts</i> , NATURE BIOTECH 2001; 19: 1176-1178.	
		Klug, M, et al., <i>Genetically Selected Cardiomyocytes From Differentiating Embryonic Stem Cells Form Stable Intracardiac Grafts</i> . J. CLIN. INVEST. 1996; 98: 216-224.	
		Koike, H, et al., <i>Efficient Biallelic Mutagenesis With Cre/Loxp-Mediated Inter-Chromosomal Recombination</i> . EMBO REPORTS 2002; 3: 433-437.	
		Kundu, R et al., <i>Targeted Inactivation Of The Coagulation Factor IX Gene Causes Hemophilia B In Mice</i> . BLOOD 1998; 92: 168-174.	
		Lai, L, et al., <i>Feasibility of Producing Porcine Nuclear Transfer Embryos by Using G2/M Stage Fetal Fibroblasts as Donors</i> , BIOL REPROD 2001; 65: 1558-1564.	

Examiner Signature	Date Considered
-----------------------	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901/04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

*Complete if Known***INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(use as many sheets as necessary)*

Sheet 4 of 6

Application Number 10/619,055

Filing Date July 14, 2003

First Named Inventor Yann Echelard

Art Unit 1632

Examiner Name

Attorney Docket Number GTC-208

		Lebel, M, et al., <i>A Deletion Within The Murine Werner Syndrome Helicase Induces Sensitivity To Inhibitors Of Topoisomerase And Loss Of Cellular Proliferative Capacity</i> . PROC. NATL. ACAD. SCI. U.S.A. 1998; 95: 13097-13102.	
		Lim, S, et al., <i>A Shortened Life Span Of EKLF-/- Adult Erythrocytes, Due To A Deficiency Of Beta -Globin Chains, Is Ameliorated By Human Gamma -Globin Chains</i> . BLOOD 1997; 90: 1291-1299.	
		Meng L, et al., <i>Rhesus Monkeys Produced by Nuclear Transfer</i> , BIOL REPROD 1997; 57: 454-459.	
		Mortensen, R, et al., <i>Production Of Homozygous Mutant ES Cells With A Single Targeting Construct</i> . MOL.CELL. BIOL. 1992; 12, 2391-2395.	
		Nagy, A, et al., <i>Targeted Mutagenesis: Analysis Of Phenotype Without Germ Line Transmission</i> . J. CLIN. INVEST. 1996; 97: 1360-1365.	
		Qu, C.-K, et al., <i>Biased Suppression Of Hematopoiesis And Multiple Developmental Defects In Chimeric Mice Containing Shp-2 Mutant Cells</i> . MOL. CELL. BIOL. 1998; 18: 6075-6082.	
		Sakai, E, et al., <i>Recombination And Transcription Of The Endogenous Ig Heavy Chain Locus Is Effected By The Ig Heavy Chain Intronic Enhancer Core Region In The Absence Of The Matrix Attachment Regions</i> . PROC. NATL. ACAD. SCI. U. S. A. 1999; 96: 1526-1531.	
		Saleque, S, et al., <i>The Zinc-Finger Proto-Oncogene Gfi-1b Is Essential For Development Of The Erythroid And Megakaryocytic Lineages</i> . GENES & DEV. 2002; 16: 301-306.	

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901/04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

6

Application Number

10/619,055

Filing Date

July 14, 2003

First Named Inventor

Yann Echelard

Art Unit

1632

Examiner Name

Attorney Docket Number

GTC-208

		Soudais, C, et al., <i>Targeted Mutagenesis Of The Transcription Factor GATA-4 Gene In Mouse Embryonic Stem Cells Disrupts Visceral Endoderm Differentiation In Vitro</i> . DEVELOPMENT 1995; 121: 3877-3888.	
		Sowell, M et al., <i>Targeted Inactivation Of Alpha I2 Or Alpha I3 Disrupts Activation Of The Cardiac Muscarinic K+ Channel, IK+ACh, In Intact Cells</i> , PROC. NATL. ACAD. SCI. U.S.A. 1997; 94: 7921-7926.	
		Stanford, W, et al., <i>Expression Trapping: Identification Of Novel Genes Expressed In Hematopoietic And Endothelial Lineages By Gene Trapping In ES Cells</i> , BLOOD 1998; 92: 4622-4631.	
		Wall RJ, et al., <i>Transgenic Dairy Cattle: Genetic Engineering on a Large Scale</i> , J DAIRY SCI. 1997; 80(9): 2213-24.	
		Wilmut I, et al., <i>Viable Offspring Derived From Fetal and Adult Mammalian Cells</i> , NATURE 1997; 385: 810-813.	
		Wells DN, et al., <i>Production of Cloned Calves Following Nuclear Transfer with Cultured Adult Mural Granulosa Cells</i> , BIOL REPROD 1999; 60: 996-1005.	
		Wells, et al., <i>Cloning livestock: a return to embryonic stem cells</i> . Trends in Biotechnology. Vol. not known, no. not known, Month, not known, 1-4.	
		Weiss, M and Orkin, S, <i>In Vitro Differentiation Of Murine Embryonic Stem Cells New Approaches To Old Problems</i> . J. CLIN. INVEST. 1996; 97: 591-595.	
		Wu, Q, et al., <i>Generation And Characterization Of Mice Deficient In Hepsin, A Hepatic Transmembrane Serine Protease</i> . J. CLIN. INVEST. 1998; 101: 321-326.	

Examiner
Signature

Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901/04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	6	of	6
-------	---	----	---

Application Number 10/619,055

Filing Date July 14, 2003

First Named Inventor Yann Echelard

Art Unit 1632

Examiner Name

Attorney Docket Number GTC-208

		Yang X, et al., <i>Nuclear Totipotency of Cultured Rabbit Morulae to Support Full-Term Development Following Nuclear Transfer</i> , BIOL REPROD 1992; 47: 636-643.	
		Yong Z and L Yuqiang, <i>Nuclear-Cytoplasmic Interaction and Development of Goat Embryos Reconstructed by Nuclear Transplantation: Production of Goats by Serially Cloning Embryos</i> , BIOL REPROD. 1998; 58: 266-269.	
		Zou X, et al., <i>Generation Of Cloned Goats (Capra Hircus) From Transfected Foetal Fibroblast Cells, The Effect Of Donor Cell Cycle</i> , MOL REPROD DEV. 2002; 61: 164-172.	

Examiner Signature	Date Considered
-----------------------	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901/04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.